Mirabegron

Mirabegron
Clinical data
Trade names	Myrbetriq, Betanis, Betmiga, others
Other names	YM-178
AHFS/Drugs.com	Monograph
MedlinePlus	a612038
License data	US DailyMed: Mirabegron;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	G04BD12 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	29–35%
Protein binding	71%
Metabolism	Liver via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase
Elimination half-life	50 hours
Excretion	Urine (55%), faeces (34%)
Identifiers
	IUPAC name 2-(2-Amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide;
CAS Number	223673-61-8;
PubChem CID	9865528;
DrugBank	DB08893;
ChemSpider	8041219;
UNII	MVR3JL3B2V;
KEGG	D09535;
ChEBI	CHEBI:65349;
ChEMBL	ChEMBL2095212;
CompTox Dashboard (EPA)	DTXSID101021648 ;
ECHA InfoCard	100.226.392
Chemical and physical data
Formula	C21H24N4O2S
Molar mass	396.51 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Nc1ccc(cc1)CCNC[C@H](O)c2ccccc2)Cc3nc(sc3)N;
	InChI InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1; Key:PBAPPPCECJKMCM-IBGZPJMESA-N;

Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder. Its benefits are similar to antimuscarinic medication such as solifenacin or tolterodine. It is taken by mouth.

Common side effects include high blood pressure, headaches, and urinary tract infections. Other significant side effects include urinary retention, irregular heart rate, and angioedema. It works by activating the β₃ adrenergic receptor in the bladder, resulting in its relaxation.

Mirabegron is the first clinically available beta-3 agonist with approval for use in adults with overactive bladder. Mirabegron was approved for medical use in the United States and in the European Union in 2012. In 2022, it was the 222nd most commonly prescribed medication in the United States, with more than 1 million prescriptions. It is available as a generic medication.

In the United Kingdom it is less preferred to antimuscarinic medication such as oxybutynin.